Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600051 | 0.81 | SIGMAR1 (0.52) | SMN1; SMN2POLBCXCR4SIGMAR1HSD17B10 | |
| SCHEMBL2187236 | 0.81 | CARM1 (0.41) | CHRM2CHRM1LMNAMAPT | |
| SCHEMBL2189098 | 0.79 | HRH3 (0.44) | SIGMAR1CHRM2CHRM1LMNAMAPT | |
| Hydrochloric Acid SCHEMBL1496041 | 0.79 | SIGMAR1 (0.50) | SMN1; SMN2POLBCXCR4SIGMAR1HSD17B10 | |
| SCHEMBL22212573 | 0.79 | RAB9A (0.39) | SIGMAR1CHRM5CHRM3KDM1ACHRM2 | |
| Hydrochloric Acid SCHEMBL1495881 | 0.79 | SIGMAR1 (0.50) | SMN1; SMN2POLBCXCR4SIGMAR1HSD17B10 | |
| SCHEMBL2188091 | 0.79 | HRH3 (0.44) | SIGMAR1CHRM2CHRM1LMNAMAPT | |
| SCHEMBL3919857 | 0.79 | SIGMAR1 (0.38) | SMN1; SMN2POLBCXCR4SIGMAR1HSD17B10 | |
| SCHEMBL18457919 | 0.77 | ALOX15 (0.35) | — | |
| Piperazine SCHEMBL28216470 | 0.77 | CXCR4 (0.38) | SMN1; SMN2POLBCXCR4SIGMAR1CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220396565-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-3380469-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | CONVERGENE LLC (US) | 2018-10-03 | — | — | EP | disclosed |
| WO-2017091661-A1 | BICYCLIC BET BROMODOMAIN INHIBITORS AND USES THEREOF | STROVEL JEFFREY WILLIAM (US) | 2017-06-01 | — | — | WO | disclosed |
| WO-2015091532-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2015-06-25 | — | — | WO | disclosed |
| US-20090247559-A1 | Benzofuropyrimidinones | EXELIXIS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| EP-2097419-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | Exelixis, Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| WO-2009086264-A1 | BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS | EXELIXIS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-6683093-B2 | ENZYME INHIBITORS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-5500410-A | BACTERICIDES | GRUPPO LEPETIT S.P.A. (IT) | 1996-03-19 | — | — | US | disclosed |
| EP-0465481-B1 | NEW SUBSTITUTED ALKYLAMIDE DERIVATIVES OF TEICOPLANIN | LEPETIT SPA (IT) | 1993-11-18 | — | — | EP | disclosed |
| EP-0465481-A1 | NEW SUBSTITUTED ALKYLAMIDE DERIVATIVES OF TEICOPLANIN. | LEPETIT SPA (IT) | 1992-01-15 | — | — | EP | disclosed |
| WO-1990011300-A1 | NEW SUBSTITUTED ALKYLAMIDE DERIVATIVES OF TEICOPLANIN | GRUPPO LEPETIT S.P.A. (IT) | 1990-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247559-A1 | Benzofuropyrimidinones | F12, BRI3BP, BRD1 | SMN1; SMN2 1926/4885POLB 1929/4885CXCR4 1210/4885 |
| US-20220396565-A1 | NOVEL HETEROCYCLIC COMPOUNDS | MRPL21, F12, MRPS34 | SMN1; SMN2 2004/4885POLB 1730/4885CXCR4 961/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | SMN1; SMN2 2011/4885POLB 2009/4885CXCR4 3046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.